News

Sanofi and Mannkind have signed an exclusive licensing agreement to develop and market the latter’s inhaled insulin diabetes therapy Afrezza. Under the terms of the agreement, France-based Sanofi

The Economic Times has reported that the drug company is likely to introduce its generic drugs in Japan in three to four years after the deal with Ranbaxy

The vaccine is being developed by GSK in collaboration with scientists at the US National Institute of Allergy and Infectious Diseases (NIAID). In primates, the vaccine has already

Originally discovered and developed by Infinity Pharmaceuticals, the fatty acid amide hydrolase (FAAH) inhibitor has already been tested in the clinic in healthy volunteers and will be studied

The application covers InVivo’s Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed

The patent describes and claims a targeted drug delivery method that combines bacterial minicells and a "bispecific ligand" in a composition lacking undesirable contamination from parent bacterial cells

This syringe technology developed under its product name "ChaSyr," (pronounced chaser), allows for the sequential administration of two separate intravenous (IV) medications with a single syringe, replacing multiple

The new initiative will help restart dosing of medication for patients who participated in previous clinical studies of exon skipping drugs – a promising approach to the disease

On January 9, 2014, Avillion announced it had entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of BOSULIF.